

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

:

Adrian MERLO et al.

Mail Stop: PCT

Serial No. 10/549,665

Attorney Docket No. 2005 1392A

Filed September 19, 2005

RADIOPHARMACEUTICALS FOR CANCER DIAGNOSIS AND TREATMENT [Corresponding to PCT/EP2004/050329 Filed March 18, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

	[X]	each U.S. Patent and U.S. Patent application publication;				
	[]	each reference previously cited in the international application PCT/; and/or				
		each reference previously cited in prior parent application Serial No.				
la.	[X] Th	ais Information Disclosure Statement is submitted:				
	within three months of the filing date (or of entry into the National Stage) of the above-entitled application. or					

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure

 Statement was first cited in any communication from a foreign patent office in a

 counterpart foreign application not more than three months prior to the filing of
 the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
- 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [] a foreign patent office search report (in the English language) submitted herewith,
 - c. [] the concise explanation contained in the specification of the present application at page,
 - d. [] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [] A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Adrian MERLO et al.

Bv

Warren M. Cheek, Jr. Registration No. 33,367

Attorney for Applicants

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 July 18, 2006

Sheet 1 of 1		INFORMA	INFORMATION DISCLOSURE STATEMENT										
FORM PTO 1449 (modified) 1 U.S. DEPARTMENT OF COMMERCE					ATTY DOCKET NO. SERIAL 2005_1392A 10/549			9,665 JUL 1 8 2006 "					
PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Adrian MERLO et al.				TRADEMANN OF					
	eral sheets if necessary) ed to PTO: July 18, 2006	; ;	FILING DATE GRO September 19, 2005				GROUP						
	U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CL	ASS	SUBCLASS	SUBCLASS FILING DATE IF APPROPRIATE				
	АА												
	AB												
	AC												
	AD					ļ							
	AE			<u> </u>									
<u> </u>	AF			<u> </u>									
	AG					ļ							
	АН								,				
	AI												
	Т		FORE	EIGN PATENT	DOCUMENTS	т —		1 1					
		DOCUMENT NUMBER	DATE	co					TRANSLA YES	ATION NO			
	AJ			<u> </u>		<u> </u>							
	AK			<u> </u>				ļ					
	AL												
	AM												
	AN					ļ. <u></u>							
		OTHER	DOCUMENT(S) (I	Including Autho	or, Title, Date, Pertind	ent Page:	s, Etc.)						
	AO	A. Harrison et al., "The <i>In Vitro</i> Release of ⁹⁰ Y from Cyclic and Acyclic Ligand-Antibody Conjugates", Nucl. Med. Biol., Vol. 18, No. 5, pp. 469-476, 1991.											
	AP	V. Alexander, "Design and Synthesis of Macrocyclic Ligands and Their Complexes of Lanthanides and Actinides", Chem. Rev., Vol. 95, pp. 273-342, 1995.											
	AQ												
EXAMINER					DATE CONSIDER	₹ED							